Vladimir Shnaydman, PhD

Portfolio simulation may be an effective tool to forecast achievability of COVID-19 portfolio strategic goals, including risk mitigation to boost vaccines development and production.

Policymakers should break with drug and biotech norms and apply risk-based portfolio simulations to understand the global portfolio of COVID-19 vaccines.

Optimization model evaluates the benefits of selecting a portfolio of investigative sites based on advanced analytical models.

Site selection is one of the most important and at the same time challenging problems in clinical trials planning. Poor site selection may cause enrollment delays, resource waste on low or zero enrollment, and even potentially compromise trial results.